18F-PSMA-1007

Comparison of fluoro-18-labeled quinoline PSMA (18F-PSMA-7Q) and 18F-PSMA-1007 in PET imaging of prostate cancer

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

18F-PSMA-1007 PET/CT Imaging in Patients with Biochemically Recurrent or High-risk Prostate Cancer

18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer

Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer.

99mTc-MIP-1404 SPECT/CT for primary PROstate cancer STAging: comparative prospective, randomized trial to present guideline imaging, PROSTAMIP

18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

A randomized trial comparing conventional "salvage" radiotherapy and individualized PSMA-PET/CT targeted treatment in patients with biochemical recurrence after prostate cancer surgery

Evaluation of PSMA-PET and mpMRI in high-risk prostate cancer – using histopathologic validation

Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).

Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007

PRISMA-PET - Primary Staging of Prostate Cancer With PSMA

Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma

Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer

The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients